deltatrials
Completed PHASE1 INTERVENTIONAL 6-arm NCT02898207

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic High Grade Fallopian Tube Serous Adenocarcinoma Metastatic Malignant Solid Neoplasm Metastatic Primary Peritoneal Serous Adenocarcinoma Metastatic Triple-Negative Breast Carcinoma Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Breast Carcinoma Recurrent High Grade Fallopian Tube Serous Adenocarcinoma Recurrent High Grade Ovarian Serous Adenocarcinoma Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma Recurrent Triple-Negative Breast Carcinoma Refractory Fallopian Tube Serous Adenocarcinoma Refractory Ovarian Serous Adenocarcinoma Refractory Primary Peritoneal Serous Adenocarcinoma Refractory Triple-Negative Breast Carcinoma Unresectable High Grade Fallopian Tube Serous Adenocarcinoma Unresectable Malignant Solid Neoplasm Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions Olaparib Onalespib
Updated 34 times since 2017 Last updated: Apr 4, 2023 Started: May 19, 2017 Primary completion: Jul 29, 2020 Completion: Jan 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic High Grade Fallopian Tube Serous Adenocarcinoma and Metastatic Malignant Solid Neoplasm and is currently completed. National Cancer Institute (NCI) leads this study, which shows 34 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~May 2023 · 16 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

34 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Jan 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 29 earlier versions

  1. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  6. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  10. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  11. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  12. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  13. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  14. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  15. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  16. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  17. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  18. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  19. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  20. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  21. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  22. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  23. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  24. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  25. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  26. May 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE1

  27. Apr 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

  28. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE1

  29. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations